Scholar Rock Holding Corporation (SRRK) News
Track canonical SquawkNews coverage tagged to SRRK, Scholar Rock Holding Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 35 indexed stories across 16 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Scholar Rock Holding Is Maintained at Buy by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 04:06 PM UTC
L
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
Scholar Rock NASDAQ:SRRK shares continued to tumble on Tuesday as Barclays downgraded the Massachusetts-area biotech despite last week’s FDA approval of its lead asset, Isembyld, for spinal muscular atrophy, a rare neuro
REGULATION | Sep 15, 2026, 04:51 PM UTC
L
Scholar Rock Holding Price Target Raised to $72.00/Share From $65.00 by Evercore ISI Group
Ratings actions from Benzinga: GMT) Scholar Rock Holding Is Maintained at Outperform by Evercore ISI GroupRatings actions from Benzinga
NEWS | Sep 15, 2026, 04:08 PM UTC
L
Scholar Rock Holding Price Target Raised to $75.00/Share From $60.00 by Piper Sandler
Ratings actions from Benzinga: GMT) Scholar Rock Holding Is Maintained at Overweight by Piper SandlerRatings actions from Benzinga
NEWS | Sep 15, 2026, 03:51 PM UTC
L
Scholar Rock Holding Price Target Raised to $65.00/Share From $57.00 by Jefferies
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 02:58 PM UTC
L
Scholar Rock Holding Price Target Raised to $70.00/Share From $64.00 by Wedbush
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:46 PM UTC
L
Scholar Rock Holding Cut to Equal-Weight From Overweight by Barclays
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 12:46 PM UTC
L
Scholar Rock: FDA approves ISEMBYLD; company to conduct pregnancy safety study and report fractures
Scholar Rock announced FDA approval of ISEMBYLD for SMA patients on SMN2-targeted therapy and confirmed plans to meet FDA post—marketing requirements.Key Highlights:Original SEC Filing: Scholar Rock Holding Corp [ SRRK ]
REGULATION | Sep 15, 2026, 12:33 PM UTC
L
Scholar Rock Holding Price Target Raised to $70.00/Share From $65.00 by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 10:41 AM UTC
M
Scholar Rock wins FDA approval for ISEMBYLD
Scholar Rock said the FDA approved ISEMBYLD for SMA in patients age 2 and older on an SMN2-targeted therapy, and it is starting a U.S. commercial launch.
EQUITY | Sep 14, 2026, 12:05 PM UTC
L
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Scholar Rock Holding NASDAQ:SRRK surged 12% in extended trading Friday after the Food and Drug Administration approved isembyld, the company’s treatment for spinal muscular atrophy.Isembyld, also known as apitegromab-mst
REGULATION | Sep 13, 2026, 05:34 PM UTC
L
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
The U.S. Food and Drug Administration (FDA) on Friday said that it approved Scholar Rock’s (SRRK) Isembyld, the first treatment designed to target muscle loss in spinal muscular atrophy, ahead of a September 30 deadline.
REGULATION | Sep 11, 2026, 11:31 PM UTC
L
Scholar Rock Gets FDA Approval of Isembyld for Spinal Muscular Atrophy
By Josh BeckermanScholar Rock said the Food and Drug Administration approved Isembyld, or apitegromab, for the treatment of spinal muscular atrophy.The drug was approved for adults and for children two years of age and o
REGULATION | Sep 11, 2026, 10:48 PM UTC
L
SRRK: ISEMBYLD receives FDA approval as the first muscle-targeted SMA therapy, launching in the U.S
FDA approved ISEMBYLD as the first muscle-targeted therapy for SMA in patients aged 2 and older on SMN2-targeted treatment, based on robust Phase 3 data showing significant motor function improvement. U.S. launch is unde
REGULATION | Sep 11, 2026, 10:29 PM UTC
L
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biolog
REGULATION | Sep 11, 2026, 10:29 PM UTC
L
Scholar Rock Holding Corporation - ISEMBYLD US Commercial Launch Underway Product Available To Ship In Coming Days
Scholar Rock Holding Corporation NASDAQ:SRRK
NEWS | Sep 11, 2026, 10:26 PM UTC
L
US FDA approves Scholar Rock drug for rare muscle-wasting disease
The U.S. Food and Drug Administration approved Scholar Rock's NASDAQ:SRRK therapy on Friday to treat a rare genetic condition that causes muscle weakness.The therapy, sold as Isembyld, is the first muscle-targeted therap
REGULATION | Sep 11, 2026, 09:38 PM UTC
L
US FDA - Approves Isembyld For Spinal Muscular Atrophy In Patients Aged 2 Years And Older
Scholar Rock Holding Corporation NASDAQ:SRRK
REGULATION | Sep 11, 2026, 09:31 PM UTC
L
US FDA approves Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration on Friday approved Scholar Rock's NASDAQ:SRRK therapy to treat a rare genetic condition that causes muscle weakness.
REGULATION | Sep 11, 2026, 09:25 PM UTC
L
SRRK: Apitegromab nears FDA approval as a first-in-class SMA therapy, with global launch plans underway
Apitegromab is poised for FDA approval as the first muscle-targeted therapy for SMA, following strong phase III results and a successful transition to a new manufacturing facility. Broad demand is anticipated, with robus
REGULATION | Sep 10, 2026, 03:12 PM UTC
L
SRRK: Apitegromab nears FDA approval with strong data, global filings, and high launch readiness
Apitegromab is set for FDA review with strong phase III results in SMA, a robust manufacturing transition, and broad anticipated demand across age groups. Regulatory filings are advancing globally, and launch preparation
REGULATION | Sep 10, 2026, 02:43 PM UTC
L
SRRK: Apitegromab nears FDA approval with robust demand, global expansion, and a strong market position
Apitegromab is poised for FDA approval following strong phase III results and a successful switch to a compliant manufacturing facility. Demand is high across SMA patient groups, with broad label expectations and global
REGULATION | Sep 10, 2026, 02:27 PM UTC
M
SRRK FDA decision on apitegromab for SMA expected by September 30
TradingView News says a decision from the FDA on apitegromab for SMA is expected by September 30 after resolving manufacturing issues and moving production to an alternate facility. Global launches are planned.
REGULATION | Sep 09, 2026, 01:46 PM UTC
M
SRRK: FDA decision on apitegromab for SMA expected by Sept. 30
SRRK’s apitegromab for SMA is nearing FDA approval, with a decision expected by September 30 after manufacturing issue resolution and a move to an alternate facility.
REGULATION | Sep 09, 2026, 01:03 PM UTC
L
HC Wainwright maintains $65 price target on Scholar Rock
HC Wainwright & Co. maintained its $65.00-per-share price target on Scholar Rock Holding (SRRK), according to Benzinga ratings actions cited by TradingView News.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
SRRK - Scholar Rock to Present at Upcoming Investor Conferences
SRRK - Scholar Rock to Present at Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 12:04 PM UTC
L
Scholar Rock to present at upcoming investor conferences
Scholar Rock is set to present at upcoming investor conferences.
EQUITY | Aug 27, 2026, 12:00 PM UTC
L
SRRK Planned Japanese filing without additional efficacy studies is likely a mild positive for SRRK shares @ BMO
SRRK Planned Japanese filing without additional efficacy studies is likely a mild positive for SRRK shares @ BMO
EQUITY | Aug 24, 2026, 12:11 PM UTC
H
Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Usin
Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official
REGULATION | Aug 07, 2026, 08:22 PM UTC
L
SRRK - Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress wi
SRRK - Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2
REGULATION | Aug 07, 2026, 08:21 PM UTC
L
SRRK - Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
SRRK - Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
EARNINGS | Aug 06, 2026, 11:06 AM UTC
L
Scholar Rock to Present
Scholar Rock presents at conference
EQUITY | Jul 29, 2026, 12:03 PM UTC
L
SRRK Scholar Rock provides update on timing of committee for medicinal products for human use (chmp) opinion for apitegromab marketing autho
SRRK Scholar Rock provides update on timing of committee for medicinal products for human use (chmp) opinion for apitegromab marketing authorisation application (maa) for spinal muscular atrophy (sma) Scholar Rock holdin
REGULATION | Jul 20, 2026, 12:01 PM UTC
L
SRRK Scholar Rock reports new employee inducement grants under Nasdaq listing rule 5635(c)(4)
SRRK Scholar Rock reports new employee inducement grants under Nasdaq listing rule 5635(c)(4)
EQUITY | Jul 17, 2026, 08:16 PM UTC
L
SRRK Presents Research
Scholar Rock is showcasing its neuromuscular research portfolio at two conferences
EQUITY | Jun 22, 2026, 12:00 PM UTC